<DOC>
	<DOCNO>NCT00946673</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) vorinostat give concurrently stereotactic radiosurgery ( SRS ) treat non-small cell lung cancer ( NSCLCA ) brain metastasis patient 1-4 lesion .</brief_summary>
	<brief_title>Phase I Vorinostat Concurrent With Stereotactic Radiosurgery ( SRS ) Brain Metastases From Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>All patient age 18 year old histologically proven nonsmall cell lung cancer 14 brain metastasis , measure less 2 cm eligible . Prior surgery radiation allow long target metastatic lesion ( ) treat previous radiation . Adequate organ function ( section 3.1.10 ) . ECOG performance status 02 . Life expectancy &gt; =12 week . Systemic chemotherapy washout period &gt; =7 day . Patients previously treat whole brain irradiation , pediatric patient ( age &lt; 18 ) , pregnant woman , patient unable give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>